Skip to main content
Fig. 3 | Journal of Translational Medicine

Fig. 3

From: Prediction of treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer by analysis of immune checkpoint protein expression

Fig. 3

Analysis of the correlation with outcome of 61 TNBC and 45 HER2+BC patients. In 61 TNBC cases, DFS was significantly longer in patients with low, compared to high, PD-1 and PD-L1 expressions (p = 0.001, log-rank) (p = 0.036, log-rank) (a, b). DFS did not differ significantly between patients with low vs high PD-L2 expression (p = 0.665, log-rank) (c). In 45 HER2+BC cases, DFS was not significantly longer in patients with low, compared to patients with high, PD-1, PD-L1 and PD-L2 expressions (p = 0.632, p = 0.556, p = 0.421, log-rank, respectively) (d, e, f)

Back to article page